Susan L. Kelley, MD has just been named a Yale University Entrepreneur-in-Residence (EIR).  Dr. Kelley is currently a Director at Daré Bioscience (formerly Cerulean Pharma), Deciphera Pharmaceuticals and Ideaya Biosciences. She was also a Director at Immune Design, Inc from 2016 until its acquisition by Merck & Co in 2019, a Director at ArQule, Inc from 2011 until its acquisition by Merck &Co in 2020 and a Director at VBL Therapeutics until 2020.

Upon beginning her new role as an EIR, Kelley said: “During my 30+ years in research and development in the biopharmaceutical industry, I have witnessed many impressive innovations that emerged from premier academic research and clinical centers such as Yale.  I look forward to providing both assistance and guidance to Yale researchers to enhance the chances for successful translation of new discoveries into meaningful therapeutic advances. "

“We are extremely fortunate to have Susan join us as an EIR,” James Boyle, who leads OCR’s Entrepreneur-in-Residence program commented. “She brings more than 3 decades of insight to the consistently-evolving biopharmaceutical industry. Her wealth of experience as a board member for both private and public companies makes her a unique resource to the Yale community. Having held leadership roles in both for-profit and non-profit biotech organizations is a testament to her versatility.”

For questions regarding Yale Venture's EIR program, please contact Dr. Boyle, Executive Director, Faculty Entrepreneurship & Venture Development.

Currently, the Yale Entrepreneurs-in-Residence (EIRs) roster includes 65 industry professionals that specialize in various areas. Each has deep operational experience and has gone through the process of turning new technologies to new businesses. These experts act as an early “sounding board” for Yale innovators contemplating a new startup. In a logical, stepwise fashion, EIRs help frame both the risks and the benefits of starting a new company, asking relevant questions about everything from the science, to the business, to the market and helping faculty chart a successful path forward. Each EIR has decades of practical private-sector experience in building their own companies and valuable connections with industry and investor communities. 

MEET YALE'S ENTREPRENEURS-IN-RESIDENCE

About Yale's Office of Cooperative Research:

Since its founding in 1982, the Yale Venture (OCR) has built a significant portfolio of inventions and patents and has grown into an engine of regional economic development. Its mission is to facilitate the translation of research from Yale’s labs into products and services that benefit society. OCR is recognized as a leading force for catalyzing economic growth by identifying, counselling and nurturing early-stage technologies and guiding the transition into robust companies. More information is available https://ocr.yale.edu